Scorpion Therapeutics

About

Scorpion Therapeutics is a precision oncology company that broadens the reach and impact of precision medicine for cancer patients.

Boston,Massachusetts,United States
51 - 100

Highlights

Details

Last Funding Type: Series B
Last Funding Money Raised: $162M
Industries: Biotechnology,Health Care,Life Science
Founded date: Jan 1, 2020
Number Of Employee: 51 - 100
Operating Status: Active

Scorpion Therapeutics was founded to broaden the reach and impact of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0. Scorpion’s experienced leadership team is executing a fit-to-purpose model to efficiently unlock the next generation of precision oncology.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

2

$270M

Scorpion Therapeutics has raised a total of $270M in funding over 2 rounds. Their latest funding was raised on Jan 7, 2021 from a Series B round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jan 7, 2021	Series B	$162M	15	Boxer Capital EcoR1 Capital Vida Ventures	—	Detail
Oct 26, 2020	Series A	$108M	5	Atlas Venture Omega Funds Vida Ventures	—	Detail

Investors

Number of Lead Investors

Number of Investors

6

16

Scorpion Therapeutics is funded by 16 investors. Boxer Capital and EcoR1 Capital are the most recent investors.

Investor Name	Lead Investor	Funding Round
Boxer Capital	Yes	Series B
EcoR1 Capital	Yes	Series B
Vida Ventures	Yes	Series B
Abingworth	—	Series B
Atlas Venture	—	Series B
Casdin Capital	—	Series B
Invus	—	Series B
Janus Henderson Investors	—	Series B
Logos Capital	—	Series B
Nextech Invest	—	Series B